STANFORD UNIVERSITY

The cell separation market is expected to grow from USD 9.1 billion in 2023 to USD 22.3 billion by 2033, driven by tech advancements, biopharmaceutical demand, and increased investments. Key techniques include centrifugation and MACS, with North America leading and Asia-Pacific expected to grow fastest. Notable developments include Terumo's partnership with CiRA Foundation for iPS cell automation and significant investments in healthcare technologies.

Scientists use a food dye to make mouse skin temporarily transparent, allowing observation of organs and blood vessels. The dye, FD&C Yellow No. 5, modifies the refractive index of tissue to match proteins and fats, enhancing light transmission. The process is reversible and could revolutionize biomedical research and healthcare applications.

CCR West celebrates its 40th anniversary with a focus on CAR T-cell therapy and precision medicine, featuring cutting-edge research and presentations by leading experts in rheumatology.

Scientists used a common food dye, tartrazine, to render mouse skin transparent, revealing blood vessels and organs. The technique, funded by the U.S. National Science Foundation and published in Science, could potentially aid in blood drawing, tattoo removal, and cancer detection. The dye, safe and inexpensive, works by reducing light scattering in skin, making it translucent.

A common food dye can temporarily make skin, muscle, and connective tissues transparent, revealing internal organs and blood vessels in mice. The dye, when washed off, restores normal skin color. Researchers believe this could lead to non-invasive diagnostic applications in humans.

Zachary Freyberg modified bromocriptine to separate dopamine effects in brain vs. periphery, finding it entered brain more slowly and stayed longer in body. This could lead to better antipsychotic drug side effect management.

A fentanyl vaccine developed by University of Houston researchers is expected to enter clinical trials mid-next year, aiming to prevent the opioid from entering the brain and causing overdose. The vaccine, successful in animal studies, is licensed to Ovax, which raised over $10 million for its production and testing. Despite challenges, including lengthy clinical trial processes and stigma around addiction, the vaccine is seen as a potential tool in the fight against the opioid crisis.

Linvoseltamab, a BCMA bispecific antibody, showed efficacy in relapsed/refractory multiple myeloma with an objective response rate of 70.9%, but requires aggressive supportive care to manage high infection risks, especially in communities without clinical trial experience. The importance of supportive care, including intravenous immunoglobulin, and potentially reducing dosing frequency to mitigate infection risks, was emphasized.

Multiple biotech companies raise significant funds for various medical advancements, including $600M for Symbiotic Capital targeting biotechnology, medical devices, diagnostics, and synthetic biology; $165M Series A for Third Arc Bio's multifunctional antibodies for oncology and autoimmunity; $144M Series B for Outpace Bio's AI-powered cell therapies for solid tumors; and others ranging from $126M for Halda Therapeutics' RIPTAC cancer therapies to $5M for Kano Therapeutics' targeted, non-viral DNA insertion technology.